ライフサイエンスコーパス: weight reduction

1 ments in KCCQ-CSS and 6MWD for each 10% body weight reduction).

2 support, joint movement, impact protection, weight reduction).

3 be one mechanism that induces bone loss with weight reduction.

4 n to attenuate the bone loss associated with weight reduction.

5 ripheral glucose metabolism before and after weight reduction.

6 ric surgery leads to substantial and durable weight reduction.

7 health improvements associated with moderate weight reduction.

8 ive in rodent models of food intake and body weight reduction.

9 t for suppressing appetite and inducing body weight reduction.

10 ocked the effects of leptin upon satiety and weight reduction.

11 that induced by certain anorexigens used for weight reduction.

12 to develop and test effective strategies for weight reduction.

13 In some cases, NASH may be reversed with weight reduction.

14 change occurs during the earliest phases of weight reduction.

15 o week 72 in cardiometabolic risk factors by weight reduction.

16 GLP-1 receptor agonist, was associated with weight reduction.

17 rring between less than 5% and less than 20% weight reduction.

18 newer GLP-1 RAs that are more effective for weight reduction.

19 ert direct metabolic benefits independent of weight reduction.

20 ous mutants are defective with a 70-90% seed weight reduction.

21 d treatment maintained and augmented initial weight reduction.

22 rovements compared with those who maintained weight reduction.

23 n the previously reported normal range after weight reduction.

24 control, even in the absence of substantial weight reduction.

25 with fewer contact hours showed a benefit in weight reduction.

26 erwent bariatric surgery as an instrument of weight reduction.

27 ically proven mechanisms for pharmacological weight reduction.

28 abdominally obese men at baseline and after weight reduction.

29 d an increase in circulating vitamin D after weight reduction.

30 oves glycemic control, often with associated weight reduction.

31 eight reduction relative to the overall body weight reduction.

32 roup) before and after equivalent short-term weight reduction.

33 are likely to benefit most from preoperative weight reduction.

34 PED1) decreases in adipose tissue (AT) after weight reduction.

35 analysis to low-risk women eliminated birth weight reductions.

36 these interventions resulted in only modest weight reductions.

37 Despite similar weight reductions 1 year after surgery (44.6% vs. 46.6%)

38 ntion participants displayed greater 6-month weight reductions (-3.83 kg; 95% CI: -4.57 to -3.09 kg)

39 s mutant mice have stunted growth (20 to 50% weight reduction), a high postnatal death rate of 60 to

40 Weight reduction achieved through lifestyle intervention

41 isk factors by degree of tirzepatide-induced weight reduction across a wide spectrum of weight loss h

42 arkers of decongestion also favored the HIC: weight reduction (adjusted mean difference: -1.36 kg; 95

43 n 24 h food intake in rats, and over 5% body weight reduction after 14-day oral treatment in diet-ind

44 on (excluding diabetes), who achieved >=5.0% weight reduction after a 12-week intensive lifestyle int

45 glucagon-like peptide-1 receptor agonist, on weight reduction after successful intensive lifestyle in

46 Conclusions: Weight reduction alleviated subclinical inflammation and

47 abetes resulted in substantial and sustained weight reduction and a markedly lower risk of progressio

48 tment resulted in dose-dependent, reversible weight reduction and adipose tissue loss.

49 Whether weight reduction and cardiometabolic risk factor managem

50 ceptor agonist, has demonstrated substantial weight reduction and cardiovascular benefits in clinical

51 lecule degradation as evidenced by molecular weight reduction and change in monomer amount.

52 ores and consequently exhibit both molecular weight reduction and change in Z-numbers.

53 The relationship between percentage weight reduction and changes in cardiometabolic risk fac

54 Finally, the relationship between weight reduction and changes in CRP across the STEP-HFpE

55 mjd3 transgenic mice show age-dependent body weight reduction and cold intolerance, respectively.

56 We reviewed the psychosocial consequences of weight reduction and concluded that weight loss is usual

57 caffolds and medical implants, to mechanical weight reduction and control over mechanical properties.

58 The Rosa-Lkb1 mice exhibited body weight reduction and died within 6 weeks after tamoxifen

59 Weight reduction and exercise are the mainstays of treat

60 ed a nonlinear inverse relation between body weight reduction and gastric volume, confirming that VSG

61 eptide-1 receptor agonists, are effective in weight reduction and have been shown to have kidney-prot

62 ed initiation of GLP-1s, including goals for weight reduction and health; (b) baseline screening, inc

63 nomic region on mouse chromosome 7 conferred weight reduction and improved glucose tolerance in znt7-

64 with Lab4P probiotic resulted in significant weight reduction and improved small dense low-density li

65 The goals of weight reduction and improving mental and physical healt

66 demonstrated short-term efficacy in inducing weight reduction and in reversing the comorbidities of o

67 ter approach emphasizes lifestyle therapies (weight reduction and increased exercise), which target a

68 The fundamental approach is weight reduction and increased physical activity; howeve

69 to the near-intractable problem of sustained weight reduction and its underlying mechanisms.

70 der adding policies or programs that address weight reduction and maintenance as part of ongoing comp

71 tial as an adjunct to semaglutide to enhance weight reduction and mitigate weight regain.

72 P receptor antagonism enhances GLP-1-induced weight reduction and other metabolic benefits, and a pha

73 proach is lifestyle intervention, especially weight reduction and physical activity.

74 A program targeting gradual weight reduction and physical exercise continues to be t

75 Incretin therapies show promise in weight reduction and physical improvement in younger pop

76 are frequently associated with inconsistent weight reduction and serious perioperative complications

77 ir usual weight (Wt(initial)) and then after weight reduction and stabilization at 10% below initial

78 Although weight reduction and statin therapy reduce HSCRP levels,

79 tudy was to evaluate the effects of moderate weight reduction and subsequent partial weight regain on

80 s, as in the development of drugs to promote weight reduction and to reduce insulin resistance.

81 The precise role of weight reduction and ursodeoxycholic acid therapy in the

82 el results were most sensitive to utility of weight reduction and weight loss of lifestyle counseling

83 e associated renal disease is ameliorated by weight reduction and/or blockade of the renin-angiotensi

84 creased contralateral prostate invasion (46% weight reduction) and lymph node metastasis (50% inhibit

85 The MC4R genotype, postpartum weight reduction, and glycemic changes between after del

86 Few obese people are successful in long-term weight reduction, and thus there is little direct eviden

87 Weight reduction as a way to reduce risk should be inves

88 revealed suppression of food intake and body weight reduction as well as glucose-lowering effects med

89 cohort study of 3389 patients with obesity, weight reduction at 1 year was associated with the medic

90 oup had maintained a clinically important 5% weight reduction at month 12, compared with 29% of patie

91 ide-treated participants with 10% or greater weight reduction at week 36 initially randomized to plac

92 e associated with achieving a 10% or greater weight reduction at year 1.

93 d of chondroitin sulfate resulted in gel wet weight reduction but not gel destruction.

94 Tirzepatide induces weight reduction but the underlying mechanisms are unkno

95 aloric restriction is the common pathway for weight reduction, but different diets may induce weight

96 on (CR) and fasting are common approaches to weight reduction, but the maintenance is difficult after

97 factors positively related to the degree of weight reduction, but the pattern varied depending on ou

98 , low-carbohydrate diets are widely used for weight reduction, but they may also have detrimental eff

99 e increases lipolysis, which results in body weight reduction, but this increase also elevates the le

100 an alternative strategy to assist postpartum weight reduction by increasing EPA and DHA status togeth

101 Genes appear to play a minor role in weight reduction by lifestyle in children with overweigh

102 Whether weight reduction can be safely achieved through lifestyl

103 Whether rapid weight reduction can precipitate gallstone formation is

104 The greater weight reduction categories had higher percentages of fe

105 ans) and spleen were detected after a 6.2-kg weight reduction compared with a control group.

106 Weight reduction continues to be first-line therapy in t

107 lls (n = 96), or standard print materials on weight reduction (control group, n = 101).

108 Percent weight reduction correlated significantly with improveme

109 The body weight reduction could prevent 183,000 (95% CI: 171,000-

110 smokers (50.6 years), or were currently on a weight reduction diet (50.5 years).

111 , the use of acetazolamide with a low-sodium weight-reduction diet compared with diet alone resulted

112 Low-sodium weight-reduction diet plus the maximally tolerated dosag

113 d mild visual loss who received a low-sodium weight-reduction diet.

114 effect of smartphone applications (apps) on weight reduction due to the several limitations of previ

115 ater after the main meal may lead to greater weight reduction during a weight-loss program.

116 d the associations between the SNVs and body weight reduction during the intervention were evaluated

117 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review w

118 ight loss; however, a simplified approach to weight reduction emphasizing only increased fiber intake

119 e traveled, fuel-mass coefficient, secondary weight reduction factor, fuel consumption allocation, re

120 very low-calorie diet (890 kcal/d until 15% weight reduction, followed by a weight maintenance diet)

121 c silencing ablates the food intake and body weight reduction following vCA1 GLP-1R activation.

122 able dose, as compared to more than 70% body weight reduction for DNR.

123 least 4.5 kg at 6 months and maintained this weight reduction for the next 30 months had the greatest

124 ts suggest that strategies focusing on small weight reductions for the entire population may be more

125 , 6MWD and CRP were greater with larger body weight reduction (for example, 6.4-point (95% confidence

126 In a model system, we see molecular weight reduction from 58,100 to approximately 400 g mol(

127 The overall mean weight reduction from week 0 to 88 was 25.3% for tirzepa

128 the trial product estimand, mean percentage weight reductions from baseline were greater with all do

129 dations were categorized into 5 domains (ie, weight reduction goals, physical activity, nutrition, al

130 olesterol were primarily observed only after weight reductions greater than 10%.

131 centage of participants achieving additional weight reduction >=5% was met with 87.5% (s.e. 2.2) with

132 lls, NAS scores decreased significantly with weight reductions >/=10%.

133 % versus 9.1% on placebo, and 33.3% had body weight reductions >=5% versus 3.0% for placebo.

134 R/shFABP4 led to metabolic recovery and body-weight reduction (>20%).

135 iac disease should not be transplanted until weight reduction has been accomplished.

136 Weight reduction has been shown to alleviate symptoms of

137 the use of dexfenfluramine hydrochloride for weight reduction has been widely publicized since its ap

138 effects of oxytocin on food intake and body weight reduction have been demonstrated in both animal m

139 ay be a simple strategy for promoting modest weight reduction; however, the effectiveness of this str

140 s of body fatness after otherwise successful weight reduction if there were a corresponding reduction

141 initial attempt at blood pressure control by weight reduction, if indicated), and, for cigarette smok

142 Weight reduction improved blood pressure, lipid levels,

143 to the normoglycemic range with significant weight reduction in a high-fat diet (HFD) induced diabet

144 predicted achieving and sustaining HbA1c and weight reduction in A Study of Tirzepatide Once a Week V

145 rforglipron as a once-daily oral therapy for weight reduction in adults with obesity.

146 rea, which demonstrated a 68 +/- 7% thrombus weight reduction in an established rat arterial thrombos

147 s (>=24 weeks, n=17) only showed benefits in weight reduction in diet strategies compared with ad-lib

148 In vivo studies on food intake and body weight reduction in diet-induced obese (DIO) mice showed

149 1jE2 revealed decreased food intake and body weight reduction in diet-induced obese (DIO) mice.

150 38-S revealed decreased food intake and body weight reduction in diet-induced obese mice as well as o

151 that caused food intake suppression and body weight reduction in diet-induced obese rats and dogs.

152 A single dose of 10 elicited sustained body weight reduction in DIO rats for at least 21 days.

153 SED showed ~30-59% tumor volume/weight reduction in H1650 tumor model compared to DIM-P

154 Cigarette smoking promotes body weight reduction in humans while paradoxically also prom

155 The role of pretransplantation weight reduction in improving graft and patient outcomes

156 2 weeks was comparable in both groups: 18.3% weight reduction in MC4R mutation carriers versus 19.9%

157 No significant body weight reduction in mice was observed for ADNR at the ma

158 t potent effects on glucose control and body weight reduction in mice, with the dual agonist antibody

159 magnets, allowing for considerable size and weight reduction in modern applications.

160 -risk individuals, controlling pre-diabetes, weight reduction in obese individuals, lowering blood pr

161 vascular disease risk factors in response to weight reduction in obese older women.

162 ate the effectiveness of a smartphone app on weight reduction in obese or overweight individuals, bas

163 s known regarding the effects of substantial weight reduction in obese patients with HF.

164 idebart cafraglutide resulted in substantial weight reduction in participants with obesity with or wi

165 We aimed to investigate long-term effects of weight reduction in psoriasis.

166 he hindbrain, and liraglutide-dependent body weight reduction in rats was independent of GLP-1 recept

167 However, the recent finding of sustained weight reduction in response to systemic administration

168 LEAP2 (LA-LEAP2) analog induces significant weight reduction in rodent models without causing aversi

169 longed efficacy for glucose control and body weight reduction in rodents with superior in vitro and i

170 modality in terms of extent and duration of weight reduction in selected patients with acceptable op

171 he clinical utility of an app for successful weight reduction in the majority of the app users; the e

172 a discussion regarding the current state of weight reduction in the prevention and treatment of CV d

173 l energy expenditure was found, resulting in weight reduction in the sleep extension group vs the con

174 The magnitude of weight reduction in the SURMOUNT-1 trial of the dual GLP

175 se were significantly modified by postpartum weight reduction in women who had experienced GDM.

176 ded significant and clinically relevant body-weight reductions in adults with overweight or obesity,

177 Stratification identified greater body weight reductions in overweight subjects (1.88%, p < 0.0

178 ith DSS, COG112 ameliorated the loss of body weight, reduction in colon length, and histologic injury

179 o the program's interventional goals of body weight reduction, increased physical activity and improv

180 nd educational links for achieving impactful weight reduction, increased physical activity, and risk

181 ention was based on 3 lifestyle programs for weight reduction, increasing physical activity, and smok

182 Weight reduction is advocated for overweight people to r

183 e prevention of future hypertension and that weight reduction is an important therapeutic interventio

184 Treatment of NASH is unproven, but weight reduction is recommended in obese patients.

185 While weight reduction is the most commonly practiced treatmen

186 growth inhibition with acceptable host body weight reduction is therefore needed.

187 Weight reduction is typically recommended, but efficacy

188 ment with tirzepatide on maintaining initial weight reduction is unknown.

189 Switching was associated with larger weight reductions (least squares mean=2.9 kg) and a net

190 cifically, a low-sodium diet, exercise, body weight reduction, low to moderate alcohol intake, and ad

191 Although it would seem prudent to recommend weight reduction <30 kg/m2 to all patients before transp

192 Weight reduction may reduce the severity of psoriasis, b

193 asting diet strategy to show benefit in body weight reduction (mean difference -1.29 kg (95% CI -1.99

194 The main outcome was weight reduction measured as the percentage of total wei

195 a suggested that salt reduction measures and weight reduction measures should be implemented simultan

196 h on adiposity prevention and more effective weight reduction methodology are urgently needed.

197 d programs for weight maintenance as well as weight reduction must become a higher public health prio

198 This is further supported by the notion that weight reduction not only effectively reduces major card

199 eight (Wt(initial)), a subject maintaining a weight reduction of > or =10% after recent (5-8 wk) comp

200 rsists in persons who have maintained a body-weight reduction of > or =10% for >1 y.

201 ooled analysis showed an overall significant weight reduction of -0.34 kg (95% CI: -0.63, -0.04 kg; P

202 in the POWeR+F group achieved an additional weight reduction of 1.5 kg (95% CI 0.6-2.4; p=0.001) ave

203 Percentage weight change and categorical weight reduction of 10% or greater at 1 year.

204 he 36-week lead-in period experienced a mean weight reduction of 20.9%.

205 5) with an MC4R agonist and observed a body weight reduction of 4.66 +/- 2.16% (means +/- SD) over a

206 lutide group than in the placebo group had a weight reduction of 5% or more (P<0.001); the same was t

207 The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89

208 intentional weight loss coupled with actual weight reduction of 5% or more was associated only with

209 At 48 weeks, a weight reduction of 5% or more, 10% or more, and 15% or

210 body weight from baseline to 48 weeks and a weight reduction of 5% or more, 10% or more, or 15% or m

211 centage change in weight from baseline and a weight reduction of 5% or more.

212 ) in the control group, and a sustained mean weight reduction of 7.5 kg (SE 0.4) versus an increase o

213 A weight reduction of 9.8 N (1 kg) was associated with red

214 A weight reduction of at least 10% by week 36 occurred in

215 tage change in bodyweight and achievement of weight reduction of at least 5% at 68 weeks for semaglut

216 weight and the percentage of patients with a weight reduction of at least 5%.

217 ng energy efficiency in applications such as weight reduction of transportation vehicles.

218 ormone polyagonists achieve an unprecedented weight reduction of up to ~20%-30%, offering a pharmacol

219 ot have a measurable impact on the molecular weight reduction of waxy flour.

220 Body-weight reductions of 20% or more, 25% or more, and 30% o

221 A 48-week phase 2 obesity study demonstrated weight reductions of 22.8% and 24.2% with retatrutide 8

222 nd third trimesters of pregnancy, with birth weight reductions of 34.74 (95% CI, -57.51 to -11.97) an

223 In the intention-to-treat analysis, weight reductions of 4.0 +/- 0.5 kg (5.3%), 3.4 +/- 0.5

224 than those in the placebo group to have body-weight reductions of 5% or more, 10% or more, 15% or mor

225 similar types of studies have reported that weight reductions of as little as 4-5 kg result in norma

226 Key secondary end points included weight reductions of at least 10%, 15%, 20%, and 25% and

227 than those in the semaglutide group to have weight reductions of at least 10%, 15%, 20%, and 25%.

228 semaglutide 2.4 mg than on placebo achieved weight reductions of at least 5% (267 [68.8%] of 388 vs

229 studies show weak evidence of benefits from weight reduction on asthma outcomes.

230 ttle direct evidence regarding the impact of weight reduction on cancer risk.

231 ion between the MC4R genotype and postpartum weight reduction on changes in fasting plasma glucose (P

232 sical activity, even at moderate levels, and weight reduction on improving insulin sensitivity and re

233 s undergoing PTCA and to study the impact of weight reduction on the long-term survival of obese pati

234 Therefore, we aimed to measure the effect of weight reduction on the severity of psoriasis in obese p

235 ortant determinant of the positive effect of weight reduction on vascular function with hyperinsuline

236 avior modification, with a goal of 7% to 10% weight reduction, on clinical parameters of NASH.

237 many structural alloys, enabling significant weight reduction opportunities.

238 However, no body weight reduction or effects on glucose or insulin were o

239 her conversion rates because of insufficient weight reduction or reflux compared to RYGB (29.9% vs 5.

240 The combinations demonstrating highest weight reduction percentage for PET were selected for fu

241 The weight reduction percentage of PET powder (300 um) was 7

242 ant but may only affect adult health if such weight reduction persists into adulthood.

243 t 20 to 30 years, lifestyle changes (such as weight reduction, physical activity and medication adher

244 Weight reduction positively impacts blood pressure.

245 orted the use of performance-enhancement and weight-reduction products, and 22% of soldiers consumed

246 nd 13 normal homozygotes, were admitted to a weight reduction program of 13 +/- 3 months, with weight

247 foods and beverages during 16 wk of a 19-wk weight-reduction program (active weight loss), a 1-y mai

248 ith and without liver steatosis undergoing a weight-reduction program to test whether an effective we

249 nt children participating in a low-intensity weight-reduction program.

250 icipated in a monthly dietitian-administered weight-reduction program.

251 ntext of a culturally adapted, comprehensive weight-reduction program.

252 s, and are extensively used in aerospace for weight reduction purposes.

253 ly performed surgeries, the amount of excess weight reduction ranges from 49% for laparoscopic adjust

254 Weight reduction reduces bone mineral density (BMD) and

255 had the most significant impact on molecular weight reduction, reducing intrinsic viscosity from 1.75

256 ttenuated obesity in mice as demonstrated by weight reduction, regional fat accumulation, lipidemia,

257 Fasting triacylglycerol in addition to body weight reduction related more to glycemic load than to G

258 The ultimate benefit of weight reduction relates to the reduction of the comorbi

259 ipose tissues underwent much more pronounced weight reduction relative to the overall body weight red

260 Healthy lifestyle and weight reduction remain crucial to the prevention and tr

261 e asthma has antiinflammatory effects beyond weight reduction, requires further study.

262 festyle counseling (eg, nutrition, exercise, weight reduction) service provided at clinic visits.

263 Weight reduction significantly improved physiologic capa

264 uture studies examining the effectiveness of weight reduction strategies in reducing CAC progression

265 When over expressed, it causes dramatic weight reduction, suggesting a role in disease-related a

266 us BFKB8488A injection caused transient body weight reduction, sustained improvement in cardiometabol

267 kg/mo) were associated with greater initial weight reduction than gastric banding (2.77 kg/mo).

268 Our findings highlight that in addition to weight reduction, the control of metabolic risk factors

269 ic disease or diabetes rather than as a mere weight-reduction therapy changes demographical and clini

270 to "bariatric surgery," conceived as a mere weight-reduction therapy.

271 tance of these loci in the associations with weight reduction through lifestyle interventions has not

272 However, the additional role of weight reduction through lifestyle modification deserves

273 Most guidelines recommend weight reduction through physical activity and improving

274 We scaled up the body weight reduction to the UK adult population.

275 icant cholesterol, lipoprotein (a), and body-weight reduction (up to 7% after 1 wk) with no effect on

276 he NDNS RP population and predicted the body weight reduction using a weight loss model.

277 ation of insulin secretion in beta cells and weight reduction via the modulation of brain appetite co

278 d lean mass, and modest but significant body weight reduction was also observed in nonobese wild-type

279 Body weight reduction was due to decreases in both fat and le

280 The body weight reduction was due to reduced weight of various ti

281 Mean (SD) body weight reduction was greater with tolvaptan on day 1 (tr

282 Significant amelioration of weight reduction was noted in treated mice.

283 In the present study, to control for weight reductions, we used litters with double the numbe

284 GFR and body weight reduction were correlated.

285 Hypomorphic alleles show a 5-10% seed weight reduction when ded1 is transmitted through the ma

286 Dyspnea improved in obese participants after weight reduction, which correlated with less tracheal co

287 Weight reduction will decrease bone mass and mineral den

288 among participants with obesity who achieved weight reduction with 36-week tirzepatide treatment, wit

289 Weight reduction with daily exercise and limiting intake

290 ight in participants who had achieved >=5.0% weight reduction with intensive lifestyle intervention.

291 In this study, weight reduction with intensive risk factor management r

292 e core molecules exhibit primarily molecular weight reduction with no change in the total unsaturatio

293 ) and >=40 kg m(-)(2)) and according to body weight reduction with semaglutide after 52 weeks.

294 nea reduction, despite significantly greater weight reduction with tolvaptan (-2.4 +/- 2.1 kg vs. -0.

295 ore people can maintain clinically important weight reductions with a web-based behavioural program a

296 BS was associated with significant long-term weight reduction, with a mean BMI decrease of -14.4 kg/m

297 oglobin A(1c) were observed even with modest weight reduction, with the steepest effect occurring bet

298 sucrose diet caused profound and sustainable weight reduction without affecting food intake.

299 We also examined samples from a human weight reduction (WR) study for adipose NNMT (aNNMT) exp

300 values for water loss (WL), solid gain (SG), weight reduction (WR), retention of ascorbic acid and De